Abstract
The lung is home to a dynamic microbial population crucial to modulating immune balance. Interest in the role of the lung microbiota in disease pathogenesis and treatment has exponentially increased. In lung cancer, early studies suggested an important role of dysbiosis in tumor initiation and progression. These results have helped accelerate research into the lung microbiota as a potential diagnostic marker and therapeutic target. Microbiota signatures could represent diagnostic biomarkers of early-stage disease. Lung microbiota research is in its infancy with a limited number of studies and only single-center studies with a significant methodological variation. Large, multicenter longitudinal studies are needed to establish the clinical potential of this exciting field.
Reference103 articles.
1. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy;Ocáriz-Díez;Front. Oncol.,2020
2. Control of immunity by the microbiota;Ansaldo;Annu. Rev. Immunol.,2021
3. Microbiome dysbiosis in lung cancer: From composition to therapy;Liu;NPJ Precis. Oncol.,2020
4. The microbiome and the respiratory tract;Dickson;Annu. Rev. Physiol.,2016
5. Sender, R., Fuchs, S., and Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol., 2016. 14.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献